Identification and biological characteristics of six Pseudomonas aeruginosa phage strains
Fan Zhang,Hao Chen,Peng-cheng Liu,Hai-min Wang,Zhi-bin Li,Yu-min Li,Xing-ming Ma
DOI: https://doi.org/10.13885/j.issn.1000-2812.2017.06.007
2017-01-01
Abstract:Objective To identify the Pseudomonas aeruginosa phage (PaP) and analyze its basic biological characteristics,such as morphology,lysis character.To determinate the multiplicity of infection (MOI),and to carry out pharmacokinetic studies of PaP 106.Methods PaP was isolated from Lanzhou city sewage samples by using 0.22 tm filtration and purified by using a double-layer agar plate.Lytic capacity of six strains of phage was measured by clinical multi drug resistant Pseudomonas aeruginosa (MDRPa).The morphology of phage106 was determined by transmission electron microscope (TEM).The host bacteria were infected with PaP106 at different MOI (10-1,10-2,10-3,10-4,10 5,10-6,and 10-7),and the optimal MOI of PaP106 was determined by the concentration of PaP.To evaluate the difference between different injection pathways (intraperitoneal,intramuscular and subcutaneous injections),and pharmacokinetic phage studies of PaP 106 were conducted.The dose of infection was 1 × 1010 pfu/mL PaP106 100 μL.The mice were dead on 0.5,1,3,6,12,24,and 36 h after intervention.The concentration of phage was measured within blood,liver,and spleen.Results Six strains of PaP had different morphologies.The PaP specifically infected and lysed between 25%-75% bacterium isolates,and the lysis volume of PaP106 was highest (75%).The optimal MOI of PaP106 was 1 × 10-6.The time to peak of intraperitoneal injection was earlier than intramuscular injection and subcutaneous injection in blood,liver,and spleen by injecting PaP106 in vivo.Conclusion PaP106 had a powerful lysis of Pseudomonas aeruginosa.The distribution and time to peak of PaP106 was earliest in blood,liver,and spleen by intraperitoneal injection.Our study has paved a way to the further study of PaP106,and support autophage as an antibiotic for treating patients with multi drug resistant Pseudomonas aeruginosa infection in the future.